制定治疗方法来治疗阿尔茨海默氏症痴呆症:方法#2
1Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123, USA.
International journal of molecular sciences
|March 28, 2024
概括
这项研究提出了一种个性化的方法来治疗阿尔茨海默氏症痴呆症 (AD),通过针对每个患者的特定贡献因素. 作为一种潜在的治愈策略,应解决至少三个AD病变发生的操作组件.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 病变发生学研究 病变发生学研究
背景情况:
- 阿尔茨海默氏症痴呆症 (AD) 是一个重大的全球健康挑战.
- 当前的治疗模式往往缺乏个性化的治疗策略.
- 了解AD病变的多因素性质对于开发有效疗法至关重要.
研究的目的:
- 为阿尔茨海默氏症痴呆症 (AD) 提出个性化,潜在的治疗治疗策略.
- 识别和分析导致AD病变的关键组成部分.
- 评估针对轻度认知障碍 (MCI) 患者的特定,操作性病理因素的疗效.
主要方法:
- 审查和分析已公布的关于AD病原体组件的数据.
- 对MCI患者中未恢复正常认知能力的组件患病率的比较分析,与恢复正常认知能力的患者进行比较.
- 为个性化治疗确定手术病理组件.
主要成果:
- 阿尔茨海默病发病的关键组成部分包括昼夜节律障碍,糖尿病,高血压,炎症和血管异常等.
- 这些组件的患病率在MCI患者中显着更高,这些患者进展到AD.
- 已公布的数据表明,治疗三种或更多已识别的成分是必要的,以获得治愈效果.
结论:
- 一种个性化的治疗方法,针对每个患者病原发生的特定操作组件,为治愈AD提供了一个有希望的策略.
- 建议在治愈疗法中解决至少三个已识别的病理成分.
- 虽然结构性大脑变化是不可逆转的,但纠正可逆的因果因素可以使神经系统受益.
相关概念视频
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43